Freedom of Information Request: Our Reference CTMUHB_27_26

You asked:

1. **How many patients have been diagnosed with Acute Myeloid Leukaemia (AML) at your Trust in the last 12 months**

   10.

   a. **Of these patients how many are refractory/relapsed (R/R)?**
   b. **How many of the R/R patients were FLT3 positive?**

   The Health Board does not record this information centrally and has concluded that the information is exempt under S40 (2) of the Freedom of Information Act on the basis that individual patient records (personal information) would need to be reviewed to ascertain the information.

2. **How many patients have been treated for AML in the latest 12 months with the following treatments**
   - **Venetoclax with azacitidine** = *Less than 5
   - **Midostaurin** = 0
   - **Quizartinib** = 0
   - **Gemtuzumab** = 0 (intensive AML therapy commissioned to Cardiff and Vale University Health Board (CAVUHB) for further information, please contact them directly via the link provided).
   - **Ivosidenib with azacitidine** = 0
   - **Liposomal cytarabine–daunorubicin** = 0 (intensive AML therapy commissioned to CAVUHB)
   - **Oral azacitidine** = 0
   - **Gilteritinib** = 0
   - **Palliative care** = 0
   - **Enrolled in a clinical trial** = 0. CTM patients may also be referred to specialist centres for treatment and offered clinical trial participation at that centre.

   *Where the figures are less than 5, the exact figures have been withheld due to the low numbers involved.

   Where numbers are low we have considered that there is the potential for the individuals to be identified from the information provided, when considered with other information that may also be in the public domain. Also, responses under the Freedom of Information Act are made available to the public at large. The data is classed as personal data as defined under the General Data Protection Regulation (GDPR) and Data Protection Act 2018 and its disclosure would be contrary to the data protection principles and constitute as unfair and unlawful processing in regard to Articles 5, 6, and 9 of GDPR. We are therefore withholding this

detail under Section 40(2) of the Freedom of Information Act 2000. This exemption is absolute and therefore there is no requirement to apply the public interest test

3. **How many relapsed/refractory patients have been treated for AML in the last 12 months with the following treatments (This question relates to treatments administered to relapsed/refractory AML patients in clinical practice, regardless of licence status or funding route (including any off-label use).**
    - **Venetoclax with azacitidine** = 0
    - **Midostaurin** = 0
    - **Quizartinib** = 0
    - **Gemtuzumab** = 0 (intensive AML therapy commissioned to CAVUHB)
    - **Ivosidenib with azacitidine** = 0
    - **Liposomal cytarabine–daunorubicin**= 0 (intensive AML therapy commissioned to CAVUHB)
    - **Oral azacitidine** = 0
    - **Gilteritinib** = 0
    - **Palliative care** = 0
    - **Enrolled in a clinical trial** = 0. CTM patients may also be referred to specialist centres for treatment and offered clinical trial participation at that centre.

4. **Of your AML patient how many were tested as below in the last 12 months**
    - **Received an FLT3 mutation test when they were diagnosed**
    - **Received an FLT3 mutation test when their disease relapsed**
    - **Received an FLT3 mutation test when their disease became refractory**

    The Health Board does not record this information centrally and has concluded that the information is exempt under S40 (2) of the Freedom of Information Act on the basis that individual patient records (personal information) would need to be reviewed to ascertain the information.